A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This drug-drug interaction (DDI) study has been designed to investigate the effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of quizartinib and its major circulating active metabolite AC886.
Epistemonikos ID: d6dcc0a08997435dba99c1e4d343a02990977e62
First added on: May 07, 2024